Sue Smith: Yes, this is Sue. Yeah, I think, we do. I think that the stability is there and that we do expect it to pick back up. We also have some new campaigns in development that we’re very excited about. So I’m anticipating we will hit this number this year with the things that we have in place.
Tessa Romero: Okay. Great. Thanks so much for taking our questions.
Operator: Our next question comes from the line of Etzer Darout with BMO Capital Markets. Please proceed with your question.
Luke Shumway: Hi, this is Luke Shumway on for Etzer. Thanks for taking my question. Just one for me. Looking at the PK and imaging data for SADA later this year, how should we think about benchmarking that and what are you thinking about, is it a go, no go for that program?
Thomas Gad: So, thanks, Etzer. So what we are trying to achieve by, December, as we are trying to, see PK curves and imaging data, meaning we are trying to validate the mechanism of the SADA platform in terms of having the protein [lines of] (ph) tumor while rapidly clearing unbound proteins from the bloodstream and at the same time, being able to, scan the tumors with the 30 millicurie isotope dose. I think, that’s what we are aiming at for December. And I think that would be a success, internally for us.
Luke Shumway: Okay, thank you.
Operator: And our next question comes from the line of [indiscernible]. Please proceed with your question.
Unidentified Analyst: Hi, everyone. Thanks for taking my questions. I’m just wondering, if you can comment on the type of centers that are going to enroll the frontline study in neuroblastoma. How many patients are these centers treating on annual basis and you already say something when you would expect data from clinical trial? Thank you.
Thomas Gad: Hi, Vignesh, why don’t you take that?
Vignesh Rajah: Yeah. I didn’t catch that question clearly. Can you repeat that, please?
Thomas Gad: He was asking about the BCC study, number of centers, potential data readout and patient numbers.
Vignesh Rajah: Yeah. So as I mentioned earlier, we have a current ongoing study, which is a single arm Phase 2, which we are aiming to transition to a study that could potentially lead to a label expansion and that transition we anticipate to take place in quarter one next year. So what will happen to the patients in the current ongoing recruitment study will of course contribute [Technical Difficulty] overall safety evaluation of the combination and induction. But the proposed new randomized study will include a number of sites which are affiliated with the BCC network, which is currently about fifty sites in US, Canada, and also, they have sites in Europe. They’re also very keen to expand it out to other centers internationally outside of the US to accelerate the recruitment for this randomized study.
The protocol is still in draft stage at the moment. But as I mentioned earlier on in the presentation part, we are looking at approximately 270 patients in total to be randomized in this study. We anticipate that will take anywhere between four to five years to complete enrollment. And based on the data, and we’re also looking at the ability of interim analysis and how that will impact as well. All of this is subject, of course, to discussions with the FDA, which we are planning later this year. And subject to all this data coming through being positive, yes, as I mentioned, we hope this will lead to sufficient data to expand our label on naxitamab in induction treatment. Does that answer your question?
Unidentified Analyst: Yeah. Great. Thank you very much. And have a nice weekend.
Thomas Gad: You too.
Operator: And we have reached the end of the question-and-answer session. I’ll now turn the call back over to management for closing remarks.
Thomas Gad: Thank you. And thank you everyone for joining us today. And happy Friday. Have a great weekend. This concludes our call.
Operator: And this does conclude today’s conference and you may disconnect your lines at this time. Thank you for your participation.
